Notice |
How to write your comments onto a webpage
[2]
| 2016.07.06 | 운영자 | 2016.11.20 | 18194 |
Notice |
How to Upload Pictures in webpages
| 2016.07.06 | 운영자 | 2018.10.19 | 32349 |
Notice |
How to use Rich Text Editor
[3]
| 2016.06.28 | 운영자 | 2018.10.19 | 5926 |
Notice |
How to Write a Webpage
| 2016.06.28 | 운영자 | 2020.12.23 | 43842 |
83 |
[Medical]2020 Hypertension Practice Guidelines
[4] | 2020.05.13 | 이한중*65 | 2020.05.14 | 325 |
82 |
The Mortality Rate of COVID19 is 20 Times That of Seasonal Flu
| 2020.05.14 | 이한중*65 | 2020.05.14 | 97 |
81 |
[Medical]A Huge Study Shows Worse Outcomes For Hydroxychloroquine
| 2020.05.22 | 이한중*65 | 2020.05.22 | 224 |
80 |
Update on Remdesivir
| 2020.05.22 | 이한중*65 | 2020.05.23 | 61 |
79 |
[Medical] EIDD-2801, The Most Promising Drug against COVID19
[1] | 2020.05.21 | 이한중*65 | 2020.05.23 | 55 |
78 |
[Medical] Effective Short Course Rx with Remdesivir
| 2020.06.01 | 이한중*65 | 2020.06.01 | 286 |
77 |
[Medical] Danger of Endurance Exercise in Elderly
[2] | 2020.06.09 | 이한중*65 | 2020.06.09 | 53 |
76 |
The Virus, What went wrong
[2] | 2020.06.18 | 온기철*71 | 2020.06.20 | 170 |
75 |
[Medical] What is a Cytokine Storm?
[2] | 2020.07.03 | 이한중*65 | 2020.07.05 | 212 |
74 |
Coronavirus airborne?
[1] | 2020.07.05 | 온기철*71 | 2020.07.09 | 62 |
» |
[Medical]Xofluza against Seasonal Flu
[1] | 2020.07.09 | 이한중*65 | 2020.07.11 | 52 |
72 |
[Medical]Pandemic and "Broken Heart Syndrome"
[4] | 2020.07.10 | 이한중*65 | 2020.07.11 | 265 |
71 |
[Medical]Vaccine May Not Protect The Elderly Well Enough
[9] | 2020.07.17 | 이한중*65 | 2020.07.25 | 86 |
70 |
[Medical] The Psychiatric Disorder in Older Adults
[4] | 2020.07.25 | 이한중*65 | 2020.07.27 | 1571 |
69 |
[Medical] COVID19 & Bradykinin Hypothesis
[1] | 2020.09.05 | 이한중*65 | 2020.09.06 | 84 |
68 |
Watch out and stay away from your grandchildren!
[2] | 2020.09.10 | 이한중*65 | 2020.09.10 | 62 |
67 |
Vaccine Story
[2] | 2020.09.09 | 이한중*65 | 2020.09.10 | 56 |
66 |
한국에는 개인병원이 있다.
[2] | 2020.09.16 | 온기철*71 | 2020.09.18 | 68 |
65 |
The Most Likely Way You’ll Get Infected With Covid-19
[7] | 2020.09.18 | 운영자 | 2020.09.20 | 212 |
64 |
COVID Deaths In U.S. By Age, Race
[3] | 2020.10.02 | 운영자 | 2020.10.02 | 139 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)